Something that stood out to me watching Dr Jay's NIH presentation was him saying that there has never been a leronlimab dose escalation study and that the 350, 525 and 700mg doses are essentially arbitrary (maybe an artifact of a delivery system?).

This isn't an issue in HIV if enough leronlimab is delivered to block viral entry but the same doses were used in the MASH study as well. He also said that in covid trials both the 700mg dose and subQ delivery were problems because a RANTES marker, calcium flux, indicated that the dose and delivery method were never going to be sufficient based on data for this marker leronlimab had shown in the past.

My point is that it's absurd, maddening, par for the course...pick your characterization, that we've used the same dose amounts for every freakin trial for no rational reason.

If another MASH trial is undertaken, or for any trial, hopefully the dose(s) used will be carefully considered and with MASH definitely needing to be subQ, there obviously needs to be enough drug delivered, which may mean more than the sacred 700mg.